FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283447987> ?p ?o ?g. }

• W4283447987 endingPage "1256" @default.
• W4283447987 startingPage "1236" @default.
• W4283447987 abstract "Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.CML is characterized by a balanced genetic translocation, t (9;22) (q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR::ABL1 fusion oncogene, which in turn translates into a BCR::ABL1 oncoprotein.Four tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, bosutinib, and nilotinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses but had no impact on survival prolongation, likely because of the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy.For CML post failure on frontline therapy, second-line options include second and third generation TKIs. Although potent and selective, these TKIs exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients' comorbidities, disease stage, and BCR::ABL1 mutational status. Patients who develop the T315I gatekeeper mutation display resistance to all currently available TKIs except ponatinib, asciminib, and olverembatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP and failure (due to resistance) of at least two TKIs, and for all patients in advanced phase disease. Older patients who have a cytogenetic relapse post failure on all TKIs can maintain long-term survival if they continue a daily most effective/least toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan and others)." @default.
• W4283447987 created "2022-06-26" @default.
• W4283447987 creator A5049385583 @default.
• W4283447987 creator A5084379902 @default.
• W4283447987 date "2022-07-06" @default.
• W4283447987 modified "2023-10-05" @default.
• W4283447987 title "Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring" @default.
• W4283447987 cites W1606656369 @default.
• W4283447987 cites W1698264213 @default.
• W4283447987 cites W1822270247 @default.
• W4283447987 cites W1964280661 @default.
• W4283447987 cites W1965303921 @default.
• W4283447987 cites W1978269924 @default.
• W4283447987 cites W1983852790 @default.
• W4283447987 cites W1987152779 @default.
• W4283447987 cites W1987374204 @default.
• W4283447987 cites W1994309500 @default.
• W4283447987 cites W1995670055 @default.
• W4283447987 cites W1995827154 @default.
• W4283447987 cites W1997730029 @default.
• W4283447987 cites W1998593414 @default.
• W4283447987 cites W2003973314 @default.
• W4283447987 cites W2006286629 @default.
• W4283447987 cites W2009972868 @default.
• W4283447987 cites W2013366836 @default.
• W4283447987 cites W2014839361 @default.
• W4283447987 cites W2015905880 @default.
• W4283447987 cites W2022158208 @default.
• W4283447987 cites W2027455169 @default.
• W4283447987 cites W2027744772 @default.
• W4283447987 cites W2028959752 @default.
• W4283447987 cites W2030488550 @default.
• W4283447987 cites W2032531836 @default.
• W4283447987 cites W2033989981 @default.
• W4283447987 cites W2034469570 @default.
• W4283447987 cites W2036798558 @default.
• W4283447987 cites W2037798465 @default.
• W4283447987 cites W2044234769 @default.
• W4283447987 cites W2047041628 @default.
• W4283447987 cites W2048620640 @default.
• W4283447987 cites W2048809946 @default.
• W4283447987 cites W2050904392 @default.
• W4283447987 cites W2052054991 @default.
• W4283447987 cites W2053131280 @default.
• W4283447987 cites W2057206328 @default.
• W4283447987 cites W2057827171 @default.
• W4283447987 cites W2058216377 @default.
• W4283447987 cites W2061440903 @default.
• W4283447987 cites W2064367288 @default.
• W4283447987 cites W2067126902 @default.
• W4283447987 cites W2069023125 @default.
• W4283447987 cites W2070507117 @default.
• W4283447987 cites W2076720738 @default.
• W4283447987 cites W2081638226 @default.
• W4283447987 cites W2083353096 @default.
• W4283447987 cites W2085342571 @default.
• W4283447987 cites W2086871637 @default.
• W4283447987 cites W2086892782 @default.
• W4283447987 cites W2091423586 @default.
• W4283447987 cites W2092606584 @default.
• W4283447987 cites W2095846263 @default.
• W4283447987 cites W2097799776 @default.
• W4283447987 cites W2097946794 @default.
• W4283447987 cites W2101635775 @default.
• W4283447987 cites W2105783133 @default.
• W4283447987 cites W2108470021 @default.
• W4283447987 cites W2110648386 @default.
• W4283447987 cites W2112942078 @default.
• W4283447987 cites W2115626434 @default.
• W4283447987 cites W2117356576 @default.
• W4283447987 cites W2117806883 @default.
• W4283447987 cites W2124196948 @default.
• W4283447987 cites W2126007139 @default.
• W4283447987 cites W2130804859 @default.
• W4283447987 cites W2134582745 @default.
• W4283447987 cites W2136065656 @default.
• W4283447987 cites W2138807703 @default.
• W4283447987 cites W2143939343 @default.
• W4283447987 cites W2147109509 @default.
• W4283447987 cites W2149132553 @default.
• W4283447987 cites W2154094925 @default.
• W4283447987 cites W2157330275 @default.
• W4283447987 cites W2157503763 @default.
• W4283447987 cites W2160007211 @default.
• W4283447987 cites W2160693099 @default.
• W4283447987 cites W2163878076 @default.
• W4283447987 cites W2166270808 @default.
• W4283447987 cites W2172189430 @default.
• W4283447987 cites W2321560918 @default.
• W4283447987 cites W2322365534 @default.
• W4283447987 cites W2331155081 @default.
• W4283447987 cites W2397234997 @default.
• W4283447987 cites W2406641958 @default.
• W4283447987 cites W2516246505 @default.
• W4283447987 cites W2537898542 @default.
• W4283447987 cites W2556518969 @default.
• W4283447987 cites W2560023695 @default.
• W4283447987 cites W2562282052 @default.

• next